DK1501517T3 - Farmaceutisk kombination til behandling af godartet hyperplasia af prostata eller til langtidsforhindring af akut urinretention - Google Patents

Farmaceutisk kombination til behandling af godartet hyperplasia af prostata eller til langtidsforhindring af akut urinretention

Info

Publication number
DK1501517T3
DK1501517T3 DK03725053T DK03725053T DK1501517T3 DK 1501517 T3 DK1501517 T3 DK 1501517T3 DK 03725053 T DK03725053 T DK 03725053T DK 03725053 T DK03725053 T DK 03725053T DK 1501517 T3 DK1501517 T3 DK 1501517T3
Authority
DK
Denmark
Prior art keywords
long
pharmaceutical combination
treatment
urinary retention
acute urinary
Prior art date
Application number
DK03725053T
Other languages
Danish (da)
English (en)
Inventor
Ludwig Mehlburger
Wolfgang Baiker
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29271571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1501517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002118392 external-priority patent/DE10218392A1/de
Priority claimed from DE2002118611 external-priority patent/DE10218611A1/de
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1501517T3 publication Critical patent/DK1501517T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DK03725053T 2002-04-24 2003-04-17 Farmaceutisk kombination til behandling af godartet hyperplasia af prostata eller til langtidsforhindring af akut urinretention DK1501517T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2002118392 DE10218392A1 (de) 2002-04-24 2002-04-24 Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie
DE2002118611 DE10218611A1 (de) 2002-04-25 2002-04-25 Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie
PCT/EP2003/004034 WO2003090753A1 (en) 2002-04-24 2003-04-17 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention

Publications (1)

Publication Number Publication Date
DK1501517T3 true DK1501517T3 (da) 2007-06-11

Family

ID=29271571

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03725053T DK1501517T3 (da) 2002-04-24 2003-04-17 Farmaceutisk kombination til behandling af godartet hyperplasia af prostata eller til langtidsforhindring af akut urinretention

Country Status (22)

Country Link
US (2) US20030225118A1 (ja)
EP (2) EP1743656A3 (ja)
JP (1) JP2005524693A (ja)
CN (1) CN1646135A (ja)
AT (1) ATE361075T1 (ja)
AU (1) AU2003227643A1 (ja)
BR (1) BR0309435A (ja)
CA (1) CA2479992A1 (ja)
CY (1) CY1107674T1 (ja)
DE (1) DE60313603T2 (ja)
DK (1) DK1501517T3 (ja)
EA (1) EA008377B1 (ja)
ES (1) ES2287474T3 (ja)
HR (1) HRP20040994A2 (ja)
IL (1) IL163976A0 (ja)
MX (1) MXPA04010408A (ja)
NO (1) NO20044333L (ja)
NZ (1) NZ536514A (ja)
PL (1) PL371430A1 (ja)
PT (1) PT1501517E (ja)
RS (1) RS92304A (ja)
WO (1) WO2003090753A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2479992A1 (en) * 2002-04-24 2003-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
EP1682183A2 (de) * 2003-11-03 2006-07-26 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einem alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
CN100451797C (zh) * 2003-11-14 2009-01-14 株式会社半导体能源研究所 显示装置及其制造法
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
CN102309495A (zh) * 2010-06-30 2012-01-11 北京润德康医药技术有限公司 一种复方制剂及其制备方法
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BRPI1103204A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab S A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
BR102013020508B1 (pt) * 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
EP3355877A4 (en) * 2015-09-30 2019-05-15 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
CN115969860A (zh) * 2021-10-14 2023-04-18 上海汇伦医药股份有限公司 一种药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
US4760071A (en) 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
NZ211145A (en) 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
DE3888378T2 (de) 1987-04-03 1994-09-29 Merck & Co Inc Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen.
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
TW369521B (en) 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6423719B1 (en) * 1999-02-16 2002-07-23 Upsher-Smith Laboratories, Inc. Method for treating benign prostate hyperplasia
WO2001021167A1 (en) * 1999-09-22 2001-03-29 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
CA2479992A1 (en) * 2002-04-24 2003-11-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention

Also Published As

Publication number Publication date
EP1501517A1 (en) 2005-02-02
IL163976A0 (en) 2005-12-18
CN1646135A (zh) 2005-07-27
PT1501517E (pt) 2007-05-31
NO20044333L (no) 2004-11-09
WO2003090753A1 (en) 2003-11-06
EA008377B1 (ru) 2007-04-27
BR0309435A (pt) 2005-02-15
CA2479992A1 (en) 2003-11-06
NZ536514A (en) 2006-11-30
EP1743656A2 (en) 2007-01-17
HRP20040994A2 (en) 2005-02-28
EP1743656A3 (en) 2007-03-07
EP1501517B1 (en) 2007-05-02
ES2287474T3 (es) 2007-12-16
ATE361075T1 (de) 2007-05-15
JP2005524693A (ja) 2005-08-18
MXPA04010408A (es) 2005-02-17
AU2003227643A1 (en) 2003-11-10
PL371430A1 (en) 2005-06-13
DE60313603D1 (de) 2007-06-14
RS92304A (en) 2006-10-27
US20070197666A1 (en) 2007-08-23
EA200401340A1 (ru) 2005-06-30
CY1107674T1 (el) 2013-04-18
US20030225118A1 (en) 2003-12-04
WO2003090753A8 (en) 2004-11-04
DE60313603T2 (de) 2008-01-03

Similar Documents

Publication Publication Date Title
CY1107674T1 (el) Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων
DK0968208T3 (da) Quinolin- og quinazolin-forbindelser som er nyttige i terapi især til behandling af godartet prostatisk hyperplasia
DK1955700T3 (da) Terapeutisk behandling af androgenreceptor-betingede lidelser
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
DK1011648T3 (da) Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer
EA200301104A1 (ru) Антиангиогенная комбинированная терапия для лечения онкологических заболеваний
DK1140181T3 (da) Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi
BR9714394A (pt) Inibidores da atividade enzimática de psa
DK1429756T3 (da) Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
ECSP077247A (es) Trans - clomifeno para el tratamiento de la hipertrofia prostatica benigna, cancer prostatico, hipogonodismo, trigliceridos elevados y alto colesterol
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
DK1534388T3 (da) Bruseanordning
DK1054868T3 (da) Substituerede pyridinoarylpiperaziner egnede til behandling af prostatahyperplasi
WO2007141661A3 (en) Herbal compositions for the prevention or treatment of benign prostatic hyperplasia
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
GB0301016D0 (en) Treatment of benign prostatic hyperplasia
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
SI1501517T1 (sl) Farmacevtska kombinacija za zdravljenje benigne hiperplazije prostate ali za dolgotrajno preprečevanje akutne retencije urina
DE69807166D1 (de) Prostata-spezifische Antigen Inhibitore
ATE479708T1 (de) EIN ßBACHß G-PROTEIN GEKOPPELTER REZEPTOR UND DAFÜR KODIERENDE POLYNUCLEOTIDE
WO2002077162A3 (en) Gene (t23490) associated with benign prostatic hyperplasia
MX9710075A (es) Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna.